Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 10/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 2/20 | 0.41 |
| ▸ | MMP13 | P45452 | 2/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | WDR91 | A4D1P6 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6409104 | 0.99 | UTS2R (0.44) | UTS2RCNR2MMP1MMP13MMP9 | |
| SCHEMBL6410848 | 0.96 | CCR5 (0.43) | UTS2RMMP1MMP13MMP9ADAM17 | |
| Hydrochloric Acid SCHEMBL6410841 | 0.95 | CCR5 (0.42) | UTS2RMMP1MMP13MMP9ADAM17 | |
| SCHEMBL6415469 | 0.93 | UTS2R (0.42) | UTS2RCNR2MMP1MMP13MMP9 | |
| SCHEMBL6409321 | 0.93 | UTS2R (0.42) | UTS2RCNR2MMP1MMP13MMP9 | |
| Hydrochloric Acid SCHEMBL6415463 | 0.93 | UTS2R (0.42) | UTS2RCNR2MMP1MMP13MMP9 | |
| SCHEMBL6412179 | 0.92 | MMP1 (0.44) | UTS2RMMP1MMP13MMP9ADAM17 | |
| Hydrochloric Acid SCHEMBL6412173 | 0.91 | MMP1 (0.43) | UTS2RMMP1MMP13MMP9ADAM17 | |
| Hydrochloric Acid SCHEMBL6410495 | 0.91 | UTS2R (0.47) | UTS2RCNR2MMP1MMP13MMP9 | |
| Hydrochloric Acid SCHEMBL6409228 | 0.91 | UTS2R (0.43) | UTS2RCNR2MMP1MMP13MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA INC (CA) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | CXCR1, CXCR4, CXCR2 | UTS2R 126/4885CNR2 180/4885MMP1 873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.